RBC Capital raised the firm’s price target on NeueHealth to $8 from $7 and keeps a Sector Perform rating on the shares. The firm is updating its model as it sees the company’s liquidity improving folloing the sale of its California Medicare Advantage business, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NEUE: